MedPath

Creating a Laparoscopic Banded Sleeve Gastrectomy

Not Applicable
Active, not recruiting
Conditions
Morbid Obesity
Interventions
Device: Banded Sleeve Gastrectomy
Device: Standard SG
Registration Number
NCT04610099
Lead Sponsor
Rijnstate Hospital
Brief Summary

A Sleeve Gastrectomy (SG) is on the long term not always successful in every patient because weight regain can occur. An intervention to prevent weight regain in the future is to place a silicone band (non-adjustable) around the sleeve (Banded-Sleeve Gastrectomy: BSG) which increases weight loss and decreases weight regain on the longer term. The question is whether primary application of a banded sleeve gives a greater weight loss and / or prevent weight regain in the future versus a standard sleeve gastrectomy.

Detailed Description

A Sleeve Gastrectomy (SG) is on the long term not always successful in every patient because weight regain can occur. An intervention to prevent weight regain in the future is to place a silicone band (non-adjustable) around the sleeve (Banded-Sleeve Gastrectomy: BSG) which increases weight loss and decreases weight regain on the longer term. The question is whether primary application of a banded sleeve gives a greater weight loss and / or prevent weight regain in the future versus a standard sleeve gastrectomy.

Study is a prospective, randomized, multi centre trial.

Study population: patients who qualify for a SG are eligible to participate. The primary SG patients may participate if there is a BMI of 35 kg / m2 with a morbidly obesity-related comorbidity or a BMI of 40kg / m2 or higher.

Intervention: The standard SG is compared with a banded-SG (BSG)

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
211
Inclusion Criteria
  • Alle patients who are eligible for a primary SG
Exclusion Criteria
  • Bariatric surgery in medical history
  • BMI > 60kg/m2 or a planned two-stage procedure.
  • Patients with a language barrier which may affect the compliance with medical advice
  • Patients with a disease not related to morbid obesity, such as Cushing or drug related.
  • Chronic bowel disease for example Crohn's disease or colitis Colitis.
  • Renal impairment (MDRD <30) or hepatic dysfunction (liver function twice the normal values)
  • Pregnancy during follow-up
  • Patients with treatment-resistant reflux symptoms. Defined as reflux persistent symptoms despite the use of a minimum dose of proton-pump inhibitors

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Banded SGBanded Sleeve Gastrectomy100 patients undergo a banded sleeve gastrectomy
Standard SGStandard SG100 patients undergo a standard sleeve gastrectomy
Primary Outcome Measures
NameTimeMethod
Percentage Total Body Weight loss (%TBWL)3 years

((preoperative weight - current weight) / (preoperative weight)) x 100%. Weight loss measured in kilograms

Secondary Outcome Measures
NameTimeMethod
Reduction of comorbidities3 years

Measuring reduction of diabetes, hypertension, dyslipidemia, osteoarticular disease, OSA

Gastroesophageal reflux disease3 years

Measuring GERD-HRQL questionnaire, a higher score on the questionnaire indicates more complaints of gastroesophageal reflux disease.

Percentage Excess Weight Loss (%EWL)3 years

((Preoperative weight - current weight) / (preoperative weight - ideal weight at BMI 25)) x 100%. Weight loss measured in kilograms

Quality of life due to questionnaire3 years

SF-36; consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability

Trial Locations

Locations (3)

Rijnstate Hospital

🇳🇱

Arnhem, Gelderland, Netherlands

Zuyderland Medisch Centrum

🇳🇱

Heerlen, Limburg, Netherlands

St. Antonius Ziekenhuis

🇳🇱

Nieuwegein, Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath